“The combination of molecular and contextual tissue biomarkers represented by this venture between Flagship and Predicine will help patients everywhere by further empowering personalized medicine for global clinical trials in immuno-oncology,” says Trevor D. Johnson, Flagship Biosciences CEO.
HAYWARD, Calif. and WESTMINSTER, Colo. (PRWEB) September 20, 2018
Predicine and Flagship Biosciences are excited to announce a strategic venture. The synergistic combination of Predicine’s GeneRADAR molecular insights platform with Flagship’s artificial intelligence-enabled cTA® digital pathology platform provides complimentary and comprehensive biomarker profiling to empower clinical trials in the immuno-oncology (IO) space.
IO therapies have changed the way we think about patient selection for precision medicine. It is increasingly evident that an understanding of both the content and context of biomarkers is required to make IO therapeutic decisions. The complexity of tumor/immune interactions creates an opportunity to leverage multiple diagnostic approaches for understanding patient-specific response to immuno-oncology therapies. Thus, a composite approach is required. Predicine and Flagship work together to provide an integrated molecular and contextual tissue biomarker solution to advance the objectives of their pharmaceutical partners. This agreement also represents an expansion of Flagship’s global footprint as it works seamlessly with Predicine’s CAP-accredited precision cancer testing laboratories in China.
“We are excited to partner with Flagship, an industry leader in digital pathology that shares our commitment to advance precision medicine through innovation. We believe this alliance will greatly benefit our biopharma clients and is a further step in Predicine's goal to provide a comprehensive blood- and tissue-based biomarker profiling in support of global clinical trials, especially in the immuno-oncology space,” said Dr. Shidong Jia, Founder and CEO of Predicine.
“The combination of molecular and contextual tissue biomarkers represented by this venture between Flagship and Predicine will help patients everywhere by further empowering personalized medicine for global clinical trials in immuno-oncology” says Trevor D. Johnson, Flagship Biosciences CEO. “Flagship is proud to partner with Predicine to bring multi-dimensional insights to support complex IO clinical decisions around the world.”
Predicine is a molecular insights company that is committed to developing the best-in-class precision diagnostics and precision medicine portfolio to address the unmet medical needs worldwide. Predicine has developed "GeneRADAR", the industry's first ctDNA+ctRNA combo liquid biopsy test, to provide a comprehensive understanding of the molecular alterations in cancer. Through its integrated one-stop biomarker service facilities in US (California) and China (Shanghai, Harbin), Predicine partners with leading biopharma companies and hospitals to support global clinical trials, early cancer screening, and targeted therapy. For more, please visit http://www.predicine.com and follow Predicine on Twitter @Predicine.
About Flagship Biosciences
Flagship Biosciences Inc. delivers comprehensive tissue profiling for predictive diagnostics in drug therapy using an Artificial Intelligence (AI) enabled computational tissue analysis (cTA®) pathology analytics platform. Our intuitive data reporting gives researchers, clinicians, and drug developers the actionable information needed to drive better clinical results for patients. For more information on how Flagship accelerates drug development, please visit http://www.flagshipbio.com and follow Flagship on Twitter @FlagshipBio.